Cargando…

BCL2 overexpression: clinical implication and biological insights in acute myeloid leukemia

BACKGROUND: BCL2 protein inhibitor venetoclax (ABT-199) has been authorized by Food and Drug Administration for relapsed/refractory chronic lymphoid leukemia with 17p deletion. Although venetoclax/ABT-199 also caused cell death in acute myeloid leukemia (AML), whether it could be applied to clinical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Jing-dong, Zhang, Ting-juan, Xu, Zi-jun, Gu, Yu, Ma, Ji-chun, Li, Xi-xi, Guo, Hong, Wen, Xiang-mei, Zhang, Wei, Yang, Lei, Liu, Xing-hui, Lin, Jiang, Qian, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6599255/ https://www.ncbi.nlm.nih.gov/pubmed/31253168 http://dx.doi.org/10.1186/s13000-019-0841-1

Ejemplares similares

H19 overexpression promotes leukemogenesis and predicts unfavorable prognosis in acute myeloid leukemia
por: Zhang, Ting-juan, et al.
Publicado: (2018)

KRAS overexpression independent of RAS mutations confers an adverse prognosis in cytogenetically normal acute myeloid leukemia
por: Zhou, Jing-Dong, et al.
Publicado: (2017)

High bone marrow ID2 expression predicts poor chemotherapy response and prognosis in acute myeloid leukemia
por: Zhou, Jing-Dong, et al.
Publicado: (2017)

SOX30 methylation correlates with disease progression in patients with chronic myeloid leukemia
por: Zhang, Ting-Juan, et al.
Publicado: (2019)

Reduced protocadherin17 expression in leukemia stem cells: the clinical and biological effect in acute myeloid leukemia
por: Xu, Zi-jun, et al.
Publicado: (2019)

Venetoclax Overcomes Sorafenib Resistance in Acute Myeloid Leukemia by Targeting BCL2
por: Xu, Xi, et al.
Publicado: (2023)

Epigenetic dysregulation of NKD2 is a valuable predictor assessing treatment outcome in acute myeloid leukemia
por: Li, Xi-xi, et al.
Publicado: (2017)

Overexpression of lncRNA PANDAR predicts adverse prognosis in acute myeloid leukemia
por: Yang, Lan, et al.
Publicado: (2018)

MicroRNA-335/ID4 dysregulation predicts clinical outcome and facilitates leukemogenesis by activating PI3K/Akt signaling pathway in acute myeloid leukemia
por: Zhou, Jing-dong, et al.
Publicado: (2019)

Identification and validation of obesity-related gene LEP methylation as a prognostic indicator in patients with acute myeloid leukemia
por: Zhang, Ting-juan, et al.
Publicado: (2021)

Overexpression of HOXA10 is associated with unfavorable prognosis of acute myeloid leukemia
por: Guo, Chao, et al.
Publicado: (2020)

Hypermethylation of secreted frizzled-related proteins predicts poor prognosis in non-M3 acute myeloid leukemia
por: Guo, Hong, et al.
Publicado: (2017)

Not BCL2 mutation but dominant mutation conversation contributed to acquired venetoclax resistance in acute myeloid leukemia
por: Zhang, Xiang, et al.
Publicado: (2021)

m6A regulator-based methylation modification patterns and characterization of tumor microenvironment in acute myeloid leukemia
por: Xu, Zi-Jun, et al.
Publicado: (2022)

ALOX5AP is a new prognostic indicator in acute myeloid leukemia
por: Chen, Xin-Yi, et al.
Publicado: (2023)

Targeting Bcl-2 Proteins in Acute Myeloid Leukemia
por: Wei, Yunxiong, et al.
Publicado: (2020)

Immune Biology of Acute Myeloid Leukemia: Implications for Immunotherapy
por: Khaldoyanidi, Sophia, et al.
Publicado: (2021)

Increased MCL-1 expression predicts poor prognosis and disease recurrence in acute myeloid leukemia
por: Li, Xi-xi, et al.
Publicado: (2019)

Dysregulation of miR-200s clusters as potential prognostic biomarkers in acute myeloid leukemia
por: Zhou, Jing-dong, et al.
Publicado: (2018)

The M2 macrophage marker CD206: a novel prognostic indicator for acute myeloid leukemia
por: Xu, Zi-Jun, et al.
Publicado: (2019)

Association Analyses of TP53 Mutation With Prognosis, Tumor Mutational Burden, and Immunological Features in Acute Myeloid Leukemia
por: Wen, Xiang-mei, et al.
Publicado: (2021)

SLIT2 promoter hypermethylation predicts disease progression in chronic myeloid leukemia
por: Wu, De-long, et al.
Publicado: (2022)

Corrigendum: Targeting Bcl-2 Proteins in Acute Myeloid Leukemia
por: Wei, Yunxiong, et al.
Publicado: (2020)

Abnormal expression and methylation of PRR34‐AS1 are associated with adverse outcomes in acute myeloid leukemia
por: Nan, Fang‐yu, et al.
Publicado: (2021)

Pan‐cancer analysis identifies CD300 molecules as potential immune regulators and promising therapeutic targets in acute myeloid leukemia
por: Xu, Zi‐jun, et al.
Publicado: (2022)

Expression and prognosis analysis of DNMT family in acute myeloid leukemia
por: Zhang, Ting-Juan, et al.
Publicado: (2020)

Pan-cancer analysis reveals distinct clinical, genomic, and immunological features of the LILRB immune checkpoint family in acute myeloid leukemia
por: Xu, Zi-jun, et al.
Publicado: (2022)

SLC22A3 methylation-mediated gene silencing predicts adverse prognosis in acute myeloid leukemia
por: Gu, Yu, et al.
Publicado: (2022)

Integrated analysis reveals distinct molecular, clinical, and immunological features of B7‐H3 in acute myeloid leukemia
por: Zhang, Ling‐yi, et al.
Publicado: (2021)

Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34(+ )acute myeloid leukemia cell lines and primary sorted CD34(+ )acute myeloid leukemia cells
por: Rao, Jia, et al.
Publicado: (2011)

BCL7A is silenced by hypermethylation to promote acute myeloid leukemia
por: Patiño-Mercau, Juan Rodrigo, et al.
Publicado: (2023)

Bax, Bcl-2, and Bax/Bcl-2 as prognostic markers in acute myeloid leukemia: are we ready for Bcl-2-directed therapy?
por: Kulsoom, Bibi, et al.
Publicado: (2018)

Efficacy and safety of decitabine in treatment of elderly patients with acute myeloid leukemia: A systematic review and meta-analysis
por: He, Pin-Fang, et al.
Publicado: (2017)

Homoharringtonine is synergistically lethal with BCL-2 inhibitor APG-2575 in acute myeloid leukemia
por: Wei, Wenwen, et al.
Publicado: (2022)

Bone marrow infiltrated natural killer cells predicted the anti-leukemia activity of MCL1 or BCL2 inhibitors in acute myeloid leukemia
por: Dai, Yu-Jun, et al.
Publicado: (2021)

Epigenetic dysregulation of ID4 predicts disease progression and treatment outcome in myeloid malignancies
por: Zhou, Jing‐dong, et al.
Publicado: (2017)

Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models
por: Han, Lina, et al.
Publicado: (2020)

Comprehensive analysis of SPAG1 expression as a prognostic and predictive biomarker in acute myeloid leukemia by integrative bioinformatics and clinical validation
por: Gu, Yu, et al.
Publicado: (2022)

Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia
por: Brinton, Lindsey T., et al.
Publicado: (2020)

EZH2 dysregulation: Potential biomarkers predicting prognosis and guiding treatment choice in acute myeloid leukaemia
por: Chu, Ming‐qiang, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0rfs54e5kqul536it7nrpdaaqi